Interferon: The pathways of discovery. I. Molecular and cellular aspects

Cytokine and Growth Factor Reviews

Volumn 17, Issue 5, 2006, Pages 381-409

  Billiau, Alfons ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Action; Induction; Interferon; Production

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERFERON; INTERFERON RECEPTOR; INTERLEUKIN 6; OMEGA INTERFERON; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DRUG POTENCY; FUNCTIONAL PROTEOMICS; GENETIC TRANSDUCTION; HUMAN; IMMUNOASSAY; IMMUNOCHEMISTRY; IMMUNOGENETICS; IMMUNOPHARMACOLOGY; MOLECULAR BIOLOGY; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; VIRUS INFECTION;

EID: 33750067700     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2006.07.001     Document Type: Note

References (186)

1. Isaacs A., and Lindenmann J. Virus Interference. 1. The IFN. Proc R Soc B 147 (1957) 258-267
2. Atkins E., and Wood Jr. W.B. Studies on the pathogenesis of fever. II. Identification of an endogenous pyrogen in the blood stream following the injection of typhoid vaccine. J Exp Med 102 (1955) 499-516
3. Harris M. IFN: clinical application of molecular biology. Science 170 (1970) 1068-1070
4. Wheelock E.F. IFN-like virus inhibitor induced in human leukocytes by phytohemagglutinin. Science 141 (1965) 30-311
5. Youngner J., and Salvin S.B. Production and properties of migration inhibitory factor and IFN in the circulation of mice with delayed type hypersensitivity. J Immunol 111 (1973) 1914-1922
6. Falcoff R. Some properties of virus- and immune-induced human lymphocyte IFNs. J Gen Virol 16 (1972) 251-253
7. Stewart W.E.I., et al. IFN nomenclature. Nature 286 (1980) 110
8. Ho M. IFN-like viral inhibitor in rabbits after intravenous administration of endotoxin. Science 146 (1964) 1472-1474
9. Youngner J.S., and Stinebring W.R. IFN appearance stimulated by endotoxin, bacteria, or viruses in mice pre-treated with Escherichia coli endotoxin or infected with Mycobacterium tuberculosis. Nature 208 (1965) 456-458
10. Gresser I., Bourali C., Levy J.P., Fontaine-Brouty-Boye D., and Thomas M.T. Increased survival in mice inoculated with tumor cells and treated with IFN preparations. Proc Natl Acad Sci USA 63 (1969) 51-57
11. Lindahl P., Leary P., and Gresser I. Enhancement by IFN of the expression of surface antigens on murine leukemia L 1210 cells. Proc Natl Acad Sci USA 70 (1973) 2785-2788
12. Trinchieri G., and Santoli D. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by IFN and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 147 (1978) 1314-1333
13. Finter N.B. IFNs and IFN inducers in vivo. I. Antiviral effects in experimental animals. In: Finter N.B. (Ed). IFNs and IFN inducers (1966), North-Holland/American Elsevier, Amsterdam 295-362
14. Tyrrell D. IFN produced by cultures of calf kidney cells. Nature 184 (1959) 452-453
15. Lampson G.P., Tytell A.A., Nemes M.M., and Hilleman M.R. Purification and characterization of chick embryo IFN. Proc Soc Exp Biol Med 112 (1963) 468-481
16. Zoon K.C., Smith M.E., Bridgen P.J., zur Nedden D., Miller D.M., and Anfinsen C. Human lymphoblastoid IFN: purification, amino acid composition and amino-terminal sequence. Ann N Y Acad Sci 350 (1980) 390-398
17. Knight Jr. E., and Hunkapillar M.W. Purification, amino acid composition, and N-terminal amino acid sequence of human fibroblast IFN. Ann N Y Acad Sci 350 (1980) 385-389
18. Broeze R.J., Taira H., Jayaram B.M., and Lengyel P. Amino terminal sequence of the mouse IFN species A from Ehrlich ascites tumor cells. Ann N Y Acad Sci 350 (1980) 428-431
19. Cantell K., Hirvonen S., Kauppinen H.L., and Myllylä G. Production of human in human leukocytes from normal donors with the use of Sendai virus. In: Pestka S. (Ed). IFNs. Part A. Methods in enzymology vol. 78 (1981), Academic Press, New York 29-38
20. Cantell K., Hirvonen S., and Koistinen V. Partial purification of human leukocyte IFN on a large scale. In: Pestka S. (Ed). IFNs. Part A. Methods in enzymology vol. 78 (1981), Academic Press, New York 499-505
21. Leong S.S., and Horoscewicz J. Production and preparation of human fibroblast IFN for clinical trials. In: Pestka S. (Ed). IFNs. Part A. Methods in enzymology vol. 78 (1981), Academic Press, New York 87-101
22. Van Damme J., and Billiau A. Large-scale production of human fibroblast IFN. In: Pestka S. (Ed). IFNs. Part A. Methods in enzymology vol. 78 (1981), Academic Press, New York 101-119
23. Havell E.A., Berman B., Ogburn C.A., Berg K., Paucker K., and Vilcek J. Two antigenically distinct species of human IFN. Proc Natl Acad Sci USA 72 (1975) 2185-2187
24. Perussia B., Fanning V., and Trinchieri G. A leukocyte subset bearing HLA-DR antigens is responsible for in vitro alpha IFN production in response to viruses. Nat Immun Cell Growth Regul 4 (1985) 120-137
25. Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K., Ho S., et al. The nature of the principal type 1 IFN-producing cells in human blood. Science 284 (1999) 1835-1837
26. Finter N.B. Large-scale production of human IFN from lymphoblastoid cells. Texas Rep Med Biol (1982) 175-178
27. Kawade Y., and Yamamoto Y. Induction and production of L cell IFN. In: Pestka S. (Ed). IFNs. Part A. Methods in enzymology vol. 175-184 (1981), Academic Press, New York
28. Tovey M.G., Begon-Lours J., and Gresser I. A method for the large-scale production of potent IFN preparations. Proc Soc Exp Biol Med 146 (1974) 809-815
29. Taira H., Broeze R.J., Slattery E., and Lengyel P. Large-scale production of mouse IFNs from monolayers of Ehrlich ascites tumor cells. J Gen Virol 49 (1980) 231-234
30. Nagata S., Taira H., Hall A., Johnsrud L., Streuli M., Ecsödi J., et al. Synthesis in E. coli of a polypeptide with human leukocyte IFN activity. Nature 204 (1980) 316-320
31. Taniguchi T., Guarente L., Roberts T., Kimelman D., Douhan J.I., and Ptashne M. Expression of the human fibroblast IFN gene in E. coli. Proc Natl Acad Sci USA 77 (1980) 5230-5233
32. Goeddel D.V., Shepard H.M., Yelverton E., Leung D., and Crea R. Synthesis of human fibroblast IFN by E. coli. Nucl Acids Res 8 (1980) 4057-4074
33. Derynck R., Remaut E., Saman E., Stanssens P., De Clercq E., Content J., et al. Expression of human fibroblast IFN gene in Escherichia coli. Nature 287 (1980) 193-197
34. De Maeyer E., De Maeyer-Guignard J., and Montagnier L. IFN messenger RNA: translation in heterologous cells. Proc Natl Acad Sci USA 69 (1972) 1203-1207
35. Masucci M.G., Szigeti R., Klein E., Gruest J., Montagnier L., Taira H., et al. Effect of IFN-α1 from E. coli on some cell functions. Science 209 (1980) 1431-1435
36. Guarente L., Roberts T.M., and Ptashne M. A technique for expressing eukaryotic genes in bacteria. Science 209 (1980) 1428-1430
37. Levy D.E., Marié I., Smith E., and Prakash A. Enhancement and diversification of IFN induction by IRF-7 mediated positive feed-back. J IFN Cytokine Res 22 (2002) 87-93
38. Taylor J. Inhibition of IFN action by actinomycin D. Biochem Biophys Res Commun 14 (1964) 447-453
39. Friedman R.M., Metz D.H., Esteban R.M., Tovell D.R., Ball L.A., and Kerr I.M. Mechanism of IFN action: inhibition of viral ribonucleic acid translation in L-cell extracts. J Virol 10 (1972) 1184-1198
40. Kerr I.M., Brown R.E., and Ball L.A. Increased sensitivity of cell-free protein synthesis to double-stranded RNA after IFN treatment. Nature 250 (1974) 57-59
41. Brown G.E., Lebleu B., Kawakita M., Shaila S., Sen G.C., and Lengyel P. Increased endonuclease activity in an extract from mouse Ehrlich ascites tumor cells which had been treated with a partially purified IFN preparation: dependence on double-stranded RNA. Biochem Biophys Res Commun 69 (1976) 114-122
42. Roberts W.K., Clemens M.J., and Kerr I.M. IFN-induced inhibition of protein synthesis in L-cell extracts: an ATP-dependent step in the activation of an inhibitor by double-stranded RNA. Proc Natl Acad Sci USA 73 (1976) 3136-3140
43. Sen G.C., Lebleu B., Brown G.E., Kawakita M., Slattery E., and Lengyel P. IFN, double-stranded RNA and mRNA degradation. Nature 269 (1976) 370-373
44. Roberts W.K., Hovanessian A., Brown R.E., Clemens M.J., and Kerr I.M. IFN-mediated protein kinase and low-molecular-weight inhibitor of protein synthesis. Nature 254 (1976) 477-480
45. Kerr I.M., Brown R.E., and Hovanessian A.G. Nature of inhibitor of cell-free protein synthesis formed in response to IFN and double-stranded RNA. Nature 268 (1977) 540-542
46. Kerr I.M., and Brown M.R. pppA2′p5′A2′p5′A: an inhibitor of protein synthesis synthesized with an enzyme fraction from IFN-treated cells. Proc Natl Acad Sci USA 75 (1978) 256-260
47. Hovanessian A.G., Brown R.E., and Kerr I.M. Synthesis of low molecular weight inhibitor of protein synthesis with enzyme from IFN-treated cells. Nature 268 (1977) 537-540
48. Lebleu B., Sen G.C., Shaila S., Cabrer B., and Lengyel P. IFN, double-stranded RNA, and protein phosphorylation. Proc Natl Acad Sci USA 73 (1976) 3107-3111
49. Farrell P.J., Sen G.C., Dubois M.F., Ratner L., Slattery E., and Lengyel P. IFN action: two distinct pathways for inhibition of protein synthesis by double-stranded RNA. Proc Natl Acad Sci USA 75 (1978) 5893-5897
50. Billiau A., Edy V., Sobis H., and De Somer P. Influence of IFN on virus particle formation in oncornavirus carrier lines. II. Evidence for a direct effect on particle release. Int J Cancer 14 (1974) 335-340
51. Pitha P.M., Rowe W.P., and Oxman M.N. Effect of IFN on exogenous, endogenous, and chronic murine leukemia virus infection. Virology 70 (1976) 324-338
52. Friedman R.M., and Ramseur J.M. Inhibition of murine leukemia virus production in chronically infected AKR cells: a novel effect of IFN. Proc Natl Acad Sci USA 71 (1974) 3542-3544
53. Billiau A., Heremans H., Allen P.T., De Maeyer-Guignard J., and De Somer P. Trapping of oncornavirus particles at the surface of IFN-treated cells. Virology 73 (1976) 537-542
54. Chang E.H., Mims S.J., Triche T.J., and Friedman R.M. IFN inhibits mouse leukaemia virus release: an electron microscope study. J Gen Virol 34 (1977) 363-367
55. Shapiro S.Z., Strand M., and Billiau A. Synthesis and cleavage processing of oncornavirus proteins during IFN inhibition of virus particle release. Infect Immun (1977) 742
56. Friedman R.M., Chang E.H., Ramseur J.M., and Myers M.W. IFN-directed inhibition of chronic murine leukemia virus production in cell cultures: lack of effect on intracellular viral markers. J Virol 16 (1975) 569-574
57. Pitha P.M., Wivel N.A., Fernie B.F., and Harper H.P. Effect of IFN on murine leukaemia virus infection. IV. Formation of non-infectious virus in chronically infected cells. J Gen Virol 42 (1979) 467-480
58. Billiau A., Heremans H., Allen P.T., Baron S., and De Somer P. IFN inhibits C-type virus at a posttranscriptional, prerelease step. Arch Virol 57 (1978) 205-220
59. Aboud M., and Hassan Y. Accumulation and breakdown of RNA-deficient intracellular virus particles in IFN-treated NIH 3T3 cells chronically producing Moloney leukemia virus. J Virol 45 (1983) 489-495
60. Chang E.H., and Friedman R.M. A large glycoprotein of Moloney leukemia virus derived from IFN-treated cells. Biochem Biophys Res Commun 77 (1977) 392-398
61. Pitha P.M., Fernie B., Maldarelli F., Hattman T., and Wivel N.A. Effect of IFN on mouse leukaemia virus (MuLV). V. Abnormal proteins in virions of Rauscher MuLV produced in the presence of IFN. J Gen Virol 46 (1980) 97-110
62. Maheshwari R.K., and Friedman R.M. Production of vesicular stomatitis virus with low infectivity by IFN-treated cells. J Gen Virol 44 (1979) 261-264
63. Maheshwari R.K., Sidhu G.S., Singh A.K., Sivaram S.S., Kinchington P.R., Hay J., et al. Defective transport of herpes simplex virus glycoprotein in IFN-treated cells: role of intracellular pH. J IFN Res 14 (1994) 319-324
64. Maheshwari R.K., Demsey A.E., Mohanty S.B., and Friedman R.M. IFN-treated cells release vesicular stomatitis virus particles lacking glycoprotein spikes: correlation with biochemical data. Proc Natl Acad Sci USA 77 (1980) 2284-2287
65. Jay F.T., Dawood M.R., and Friedman R.M. IFN induces the production of membrane protein-deficient and infectivity-defective vesicular stomatitis virions through interference in the virion assembly process. J Gen Virol 64 (1983) 707-712
66. Singh V.K., Maheshwari R.K., Damewood G.P., Stephensen C.B., Oliver C., and Friedman R.M. IFN alters intracellular transport of vesicular stomatitis virus glycoprotein. J Biol Regul Homeost Agents 2 (1988) 53-62
67. Maheshwari R.K., Husain M.M., and Friedman R.M. Low infectivity of vesicular stomatitis virus (VSV) particles released from IFN-treated cells is related to glycoprotein deficiency. Biochem Biophys Res Commun 117 (1983) 161-168
68. Haller O. Inborn resistance of mice to orthomyxoviruses. Curr Topics Microbiol Immunol 92 (1981) 25-52
69. Pavlovic J., and Staeheli P. The antiviral potentials of Mx Proteins. J IFN Res 11 (1991) 215-219
70. Kochs G., and Haller O. IFN-induced human MxA GTPase blocks nuclear import of Thogoto virus nucleocapsids. Proc Natl Acad Sci USA 96 (1999) 2082-2086
71. Haller O., and Kochs G. IFN-induced Mx proteins: dynamin-like GTPases with antiviral activity. Traffic 3 (2002) 710-717
72. Engelhardt O.G., Ulrich E., Kochs G., and Haller O. IFN-induced antiviral Mx1 GTPase is associated with components of the SUMO-1 system and promyelocytic leukemia protein nuclear bodies. Exp Cell Res 271 (2001) 286-295
73. Stark G.R., and Kerr I.M. IFN-dependent signaling pathways: DNA elements, transcription factors, mutations, and effects of viral proteins. J IFN Res 12 (1992) 147-151
74. Williams B.R.G. Transcriptional regulation of IFN-stimulated genes. Eur J Biochem 200 (1991) 1-11
75. Levy D., and Darnell J.E. IFN-dependent transcriptional activation: signal transduction without second messenger involvement?. New Biol 2 (1990) 923-928
76. Velazquez L., Fellous M., Stark G.R., and Pellegrini S. A protein tyrosine kinase in the IFN alpha/beta signaling pathway. Cell 70 (1992) 313-322
77. Watling D., Guschin D., Müller M., Silvennoinen O., Witthuhn B.A., Quelle F.W., et al. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the IFN-γ signal transduction pathway. Nature 366 (1993) 166-170
78. Veals S.A., Santa M.T., and Levy D.E. Two domains of ISGF3 gamma that mediate protein-DNA and protein-protein interactions during transcription factor assembly contribute to DNA-binding specificity. Mol Cell Biol 13 (1993) 196-206
79. Shuai K., Stark G.R., Kerr I.M., and Darnell Jr. J.E. A single phosphotyrosine residue of Stat91 required for gene activation by IFN-γ. Science 261 (1993) 1744-1746
80. Leaman D.W., Leung S., Li X., and Stark G.R. Regulation of STAT-dependent pathways by growth factors and cytokines. FASEB J 10 (1996) 1578-1588
81. Buckler C.E., Baron S., and Levy H. IFN: lack of detectable uptake by cells. Science 152 (1966) 80-82
82. Vilcek J., and Rada B. Studies on an IFN from tick-borne encephalitis virus infected cells. III. Antiviral action of IF. Acta Virol 6 (1962) 9-16
83. Friedman R.M. IFN binding: the first step in establishment of antiviral activity. Science 156 (1967) 1760-1766
84. Rashidbaigi A., Langer J.A., Jung V., Jones C., Morse H.G., Tischfield J.A., et al. The gene for the human immune IFN receptor is located on chromosome 6. Proc Natl Acad Sci USA 83 (1986) 384-388
85. Mariano T.M., Kozak C.A., Langer J.A., and Pestka S. The mouse immune IFN receptor gene is located on chromosome 10. J Biol Chem 262 (1987) 5812-5814
86. Calderon J., Sheehan K.C.F., Chance C., Thomas M.L., and Schreiber R.D. Purification and characterization of the human IFN-γ receptor from placenta. Proc Natl Acad Sci USA 85 (1988) 4837-4841
87. Novick D., Orchansky P., Revel M., and Rubinstein M. The human IFN-γ receptor. Purification, characterization and preparation of antibodies. J Biol Chem 262 (1987) 8483-8487
88. Aguet M., and Merlin G. Purification of human γ IFN receptors by sequential affinity chromatography on immobilized monoclonal antireceptor antibodies and human IFN γ. J Exp Med 165 (1987) 988-999
89. Aguet M., Dembic Z., and Merlin G. Molecular cloning and expression of the human IFN-γ receptor. Cell 55 (1988) 273-280
90. Hemmi S., Peghini P., Metzler M., Merlin G., Dembic Z., and Aguet M. Cloning of murine IFN γ receptor cDNA: expression in human cells mediates high-affinity binding but is not sufficient to confer sensitivity to murine IFN γ. Proc Natl Acad Sci USA 86 (1989) 9901-9905
91. Jung V., Jones C., Kumar C., Stefanos S., O'Connell S., and Pestka S. Expression and reconstitution of a biologically active human IFN-γ receptor in hamster cells. J Biol Chem 265 (1990) 1827-1830
92. Basu M., Pace J.L., Pinson D.M., Hayes M.P., Trotta P.P., and Russell S.W. Purification and partial characterization of a receptor protein for mouse IFN g. Proc Natl Acad Sci USA 85 (1988) 6282-6286
93. Cofano F., Moore S.K., Tanaka S., Yuhki N., Landolfo S., and Appella E. Affinity purification, peptide analysis, and cDNA sequence of the mouse IFN γ receptor. J Biol Chem 265 (1990) 4064-4071
94. Hibino Y., Mariano T.M., Kumar C.S., Kozak C.A., and Pestka S. Expression and reconstitution of a biologically active mouse IFN-γ receptor in hamster cells. J Biol Chem 266 (1991) 6948-6951
95. Hibino Y., Kumar C.S., Mariano T.M., and Pestka S. Chimeric IFN-γ receptors demonstrate that an accessory factor required for activity interacts with the extracellular domain. J Biol Chem 267 (1992) 3741-3749
96. Axelrod A., Gibbs V.C., and Goeddel D.V. The IFN-γ receptor extracellular domain. Non-identical requirements for ligand binding and signalling. J Biol Chem 269 (1994) 15533-15539
97. Hemmi S., Böhni R., Stark G., Di Marco F., and Aguet M. A novel member of the IFN receptor family complements functionality of the murine IFN γ receptor in human cells. Cell 76 (1994) 803-810
98. Soh J., Donnelly R.J., Kotenko S., Mariano T.M., Cook J.R., Wang N., et al. Identification and sequence of an accessory factor required for activation of the human IFN γ receptor. Cell 76 (1994) 793-802
99. Domanski P., and Colamonici O.R. The type I IFN receptor. The long and short of it. Cytokine Growth Factor Rev 7 (1996) 143-151
100. Langer J.A., and Pestka S. IFN receptors. Immunol Today 9 (1988) 393-400
101. Colamonici O.R., D'Alessandro F., Diaz M.O., Gregory S.A., Neckers L.M., and Nordan R. Characterization of three monoclonal antibodies that recognize the IFN α2 receptor. Proc Natl Acad Sci USA 87 (1990) 7230-7234
102. Uzé G., Lutfalla G., and Gresser I. Genetic transfer of a functional human IFN alpha receptor into mouse cells: cloning and expression of its cDNA. Cell 60 (1990) 225-234
103. Colamonici O.R., Pfeffer L.M., D'Alessandro F., Platanias L.C., Gregory S.A., Rosolen A., et al. Multichain structure of the IFN-α receptor on hematopoietic cells. J Immunol 148 (1992) 2126-2132
104. Colamonici O.R., and Domanski P. Identification of a novel subunit of the type I IFN receptor localized to human chromosome 21. J Biol Chem 25 (1993) 10895-10899
105. Novick D., Cohen B., and Rubinstein M. The human IFN α/β receptor: characterization and molecular cloning. Cell 77 (1994) 391-400
106. tyk2 tyrosine kinase. Mol Cell Biol 14 (1994) 8133-8142
107. Domanski P., Witte M., Kellum M., Rubinstein M., Hackett R., Pitha P., et al. Cloning and expression of a long form of the β subunit of the IFN αβ receptor that is required for signalling. J Biol Chem 270 (1995) 21606-21611
108. Muller M., Briscoe J., Laxton C., Guschin D., Ziemiecki A., Silvennoinen O., et al. The protein tyrosine kinase JAK1 complements defects in IFN-alpha/beta and -gamma signal transduction. Nature 366 (1993) 129-135
109. Silvennoinen O., Ihle J.N., Schlessinger J., and Levy D.E. IFN-induced nuclear signalling by Jak protein tyrosine kinases. Nature 366 (1993) 583-585
110. Greenlund A.C., Farrar M.A., Viviano B.L., and Schreiber R.D. Ligand-induced IFN γ receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91). EMBO J 13 (1994) 1591-1600
111. Igarashi K., Garotta G., Ozmen L., Ziemiecki A., Wilks A.F., Harpur A.G., et al. IFN-γ induces tyrosine phosphorylation of IFN-γ receptor and regulated association of protein tyrosine kinases, Jak1 and Jak2, with its receptor. J Biol Chem 269 (1994) 14333-14336
112. Sakatsume M., Igarashi K., Winestock K.D., Garotta G., Larner A.C., and Finbloom D.S. The Jak kinases differentially associate with the α and β (accessory factor) chains of the IFN γ receptor to form a functional receptor unit capable of activating STAT transcription factors. J Biol Chem 270 (1995) 17528-17534
113. Lockart Jr. R.Z. Criteria for acceptance of a viral inhibitor as an IFN and a general description of the biological properties of known IFNs. In: Finter N.B. (Ed). IFNs and IFN inducers (1973), Elsevier Publishing, New York 11-28
114. Gewert D.R., Moore G., Tilleray V.J., and Clemens M.J. Inhibition of cell proliferation by IFNs. I. Effects on cell division and DNA synthesis in human lymphoblastoid (Daudi) cells. Eur J Biochem 159 (1984) 619-625
115. Moore G., Gewert D.R., and Clemens M.J. Inhibition of cell proliferation by IFNs. 2. Changes in processing and stability of newly synthesized DNA in human lymphoblastoid (Daudi) cells. Eur J Biochem 159 (1984) 627-635
116. 1 Cdk-complexes and activation of pocket proteins. Oncogene 18 (1999) 2798-2810
117. Rath P.C., and Aggarwal B.B. Antiproliferative effects of IFN-α correlate with downregulation of nuclear factor-κB in human Burkitt lymphoma. J IFN Cytokine Res 21 (2001) 523-528
118. Gisslinger H., Kurzrock G.H., Gisslinger B., Jiang S., Li S., Virgolini I., et al. Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by IFN-a: involvement of tumor necrosis factor as ligand for the CD95 receptor. Blood 97 (2001) 2791-2797
119. Oshima K., Yanase N., Ibukiyama C., Yamashina A., Kayagaki N., Yagita H., et al. Involvement of TRAIL/TRAIL-R interaction in IFN-α-induced apoptosis of Daudi B lymphoma cells. Cytokine 14 (2001) 193-201
120. Powell H.M., Culbertson C.G., McGuire J.M., Hoehn M.M., and Baker L.A. A filtrate with chemoprophylactic and chemotherapeutic action against MM and Semliki Forest viruses in mice. Antbiot Chemother 2 (1952) 113-118
121. Shope R.E. Therapeutic activity of a substance from Penicillium funiculosum Thom against swine influenza virus infection in mice. Am J Bot 35 (1948) 803
122. Shope R.E. An antiviral substance from Penicillium funiculosum. I. Effect upon infection in mice with swine influenza virus and Columbia SK encephalomyelitis virus. J Exp Med 97 (1953) 601-625
123. Shope R.E. An antiviral substance from Penicillium funiculosum. II. Effect of helenine upon infection in mice with Semliki Forest virus. J Exp Med 97 (1953) 627-638
124. Shope R.E. An antiviral substance from Penicillium funiculosum. III. General properties and characteristics of helenine. J Exp Med 97 (1953) 639-650
125. Shope R.E. An antiviral substance from Penicillium funiculosum. IV. Inquiry into the mechanism by which helenine exerts its antiviral effect. J Exp Med 123 (1966) 213-227
126. Rytel M.W., Shope R.E., and Kilbourne B.D. An antiviral substance from Penicillium funiculosum. V. Induction of IFN by helenine. J Exp Med 123 (1966) 577-584
127. Kleinschmidt W.J., Cline J.C., and Murphy E.B. IFN production induced by statolon. Proc Natl Acad Sci USA 52 (1964) 741-744
128. Lampson G.P., Tytell A.A., Field A.K., Nemes M.M., and Hilleman M.R. Inducers of IFN and host resistance. I. Double-stranded RNA from extracts of Penicillium funiculosum. Proc Natl Acad Sci USA 58 (1967) 782-789
129. Field A.K., Tytell A.A., Lampson G.P., and Hilleman M.R. Inducers of IFN and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc Natl Acad Sci USA 58 (1967) 1004-1010
130. Espert L., Gongora C., and Mechti N. Interféron: une barrière antivirale efficace qui a ses faiblesses. Bulletin du Cancer 90 (2003) 131-141
131. Taniguchi T., and Takaoka A. A weak signal for strong responses: IFN-α/β revisited. Nat Rev 2 (2001) 379-386
132. Servant M.J., Tenoever B., and Lin R. Overlapping and distinct mechanisms regulating IRF-3 and IRF-7 function. J IFN Cytokine Res 22 (2002) 49-58
133. Williams B.R.G., and Sen G.C. A viral on/off switch for IFN. Science 300 (2003) 1100-1101
134. Sharma S., tenOever B.R., Grandvaux N., Zhou G.-P., Lin R., and Hiscott J. Triggering the IFN antiviral response through an IKK-related pathway. Science 300 (2003) 1148-1151
135. Alexopoulou L., Holt A.C., Medzhitov R., and Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 (2001) 732-738
136. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303 (2004) 1526-1528
137. Diebold S.S., Kaisho T., Hemmi H., and Akira S. Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303 (2004) 1529-1531
138. Akira S., and Sato S. Toll-like receptors and their signaling mechanisms. Scand J Infect Dis 35 (2003) 555-562
139. O'Neill L.A.J. After the Toll Rush. Science 303 (2004) 1481-1482
140. Jiang Z., Mak T.W., Sen G., and Li X. Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proc Natl Acad Sci USA 101 (2004) 3533-3538
141. Vilcek J., Rossman T.G., and Varacalli F. Differential effects of actinomycin D and puromycin on the release of IFN induced by double-stranded RNA. Nature 223 (1969) 683
142. Vilcek J. Metabolic determinants of the induction of IFN by a synthetic double-stranded polynucleotide in rabbit kidney cells. Ann N Y Acad Sci 173 (1970) 390-403
143. Tan Y.H., Armstrong J.A., Ke Y.H., and Ho M. Regulation of cellular IFN production: enhancement by antimetabolites. Proc Natl Acad Sci USA 67 (1970) 464-471
144. Ho M., Armstrong J.A., Ke Y.H., and Tan Y.H. Unifying theory of the mechanism of IFN stimulation by poly I:C. IFN Scientific Memoranda 332/1-3(January 1970) (1970), Aries Corporation, McLean, VA, USA
145. Ho M., Ke Y.H., and Armstrong J.A. Mechanism of IFN induction by endotoxin. J Infect Dis 128S (1973) 220-227
146. Cavalieri R.L., Havell E.A., Vilcek J., and Pestka S. Induction and decay of human fibroblast IFN mRNA. Proc Natl Acad Sci USA 74 (1977) 4415-4419
147. Sehgal P.B., and Tamm I. Two mechanisms contribute to the superinduction of poly(I).poly(C)-induced human fibroblast. Virology 92 (1979) 240-244
148. Isaacs A., and Burke D.C. Mode of action of IFN. Nature 182 (1958) 1073-1074
149. Stewart W.E.I., Gosser L.B., and Lockart Jr. R.Z. Priming: a nonantiviral function of IFN. J Virol 7 (1971) 792-801
150. Abreu S.L., Bancroft F.C., and Stewart W.E.I. IFN priming. Effects on IFN messenger RNA. J Biol Chem 254 (1979) 4114-4118
151. Nir U., Maroteaux L., Cohen B., and Mory I. Priming affects the transcription rate of human IFN-beta 1 gene. J Biol Chem 260 (1985) 14242-14247
152. Fujita T., Reis L.F., Watanabe N., Kimura Y., Taniguchi T., and Vilcek J. Induction of the transcription factor IRF-1 and IFN-beta mRNAs by cytokines and activators of second-messenger pathways. Proc Natl Acad Sci USA 86 (1989) 9936-9940
153. Harada H., Fujita T., Miyamoto M., Kimura Y., Maruyama M., Furia A., et al. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 58 (1989) 729-739
154. Lenardo M.J., Fan C.M., Maniatis T., and Baltimore D. The involvement of NF-kappa B in beta-IFN gene regulation reveals its role as widely inducible mediator of signal transduction. Cell 57 (1989) 287-294
155. Fujita T., Miyamoto M., Kimura Y., Hammer J., and Taniguchi T. Involvement of a cis-element that binds an H2TF-1/NF kappa B like factor(s) in the virus-induced IFN-beta gene expression. Nucl Acids Res 17 (1989) 3335-3346
156. Reis LF, Lee TH, Fujita T, Taniguchi T, Vilcek J, 1989. Induction of IFN-β and IFN regulatory factor-1 (IRF-1) by cytokines in human fibroblasts. J IFN Cytokine Res 9S, Abstract 13-8. Abstract Book - Annual Meeting of the International Society for IFN Research - Florence, 22-27 October.
157. Sato M., Suemori H., Hata N., Asagiri M., Ogasawara K., Nakao K., et al. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 13 (2000) 539-548
158. Yeow W.S., Au W.C., Yuang Y.T., Fields C.D., Dent C.L., Gewert D.R., et al. Reconstitution of virus-mediated expression of IFN alpha genes in human fibroblast cells by ectopic IFN-regulatory factor-7. J Biol Chem 275 (2000) 6313-6320
159. Barnes B., Lubyova B., and Pitha P.M. On the role of IRF in host defense. J IFN Cytokine Res 22 (2002) 59-71
160. Billiau A., Buckler C.E., Dianzani F., Uhlendorf C., and Baron S. Induction of the IFN mechanism by single-stranded RNA: potentiation by polybasic substances. Proc Soc Exp Biol Med 132 (1969) 790-796
161. De Ley M., Van Damme J., Claeys H., Weening H., Heine J.W., Billiau A., et al. IFN induced in human leukocytes by mitogens: production, partial purification and characterization. Eur J Immunol 10 (1980) 877-883
162. Van Damme J., De Ley M., Claeys H., Billiau A., Vermylen C., and De Somer P. IFN induced in human leukocytes by concanavalin A: isolation and characterization of gamma and β-type components. Eur J Immunol 11 (1981) 937-942
163. Van Damme J., Billiau A., De Ley M., and De Somer P. An IFN-β-like or IFN-inducing protein released by mitogen-stimulated human leukocytes. J Gen Virol 64 (1983) 1819-1822
164. Van Damme J., De Ley M., Opdenakker G., Billiau A., De Somer P., and Van Beeumen J. Homogeneous IFN-inducing 22K factor is related to endogenous pyrogen and interleukin-1. Nature 314 (1985) 266-268
165. Auron P.E., Webb A.C., Rosenwasser L.J., Mucci S.F., Rich A., Wolff S.M., et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci USA 81 (1984) 7907-7911
166. March C.J., Mosley B., Larsen A., Cerretti D.P., Braedt G., Price V., et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 315 (1985) 641-647
167. Van Damme J., Opdenakker G., Billiau A., De Somer P., De Wit L., Poupart P., et al. Stimulation of fibroblast IFN production by a 22K protein from human leukocytes. J Gen Virol 66 (1985) 693-700
168. Mestan J., Digel W., Mittnacht S., Hillen H., Blohm D., Möller A., et al. Antiviral effects of recombinant tumour necrosis factor in vitro. Nature 233 (1986) 816-819
169. Wong G.H., and Goeddel D.V. Tumour necrosis factors alpha and beta inhibit virus replication and synergize with IFNs. Nature 323 (1986) 819-822
170. Ito M., and O'Malley J.A. Antiviral effects of recombinant human tumor necrosis factor. Lymphokine Res 6 (1987) 309-318
171. Van Damme J., De Ley M., Van Snick J., Dinarello C.A., and Billiau A. The role of IFN-beta 1 and the 26-kDa protein (IFN-beta 2) as mediators of the antiviral effect of interleukin 1 and tumor necrosis factor. J Immunol 139 (1987) 1867-1872
172. Reis L.F.L., Le J., Hirano T., Kishimoto T., and Vilcek J. Antiviral action of tumor necrosis factor in human fibroblasts is not mediated by B cell stimulatory factor 2/IFN-β2, and is inhibited by specific antibodies to IFN-β. J Immunol 140 (1988) 1566-1570
173. Ruggiero V., Antonelli G., Conciatori G., Gentile M., Van Damme J., and Dianzani F. The in vitro antiviral activity of tumor necrosis factor (TNF) in WISH cells is mediated by IFN-beta induction. Antiviral Res 11 (1989) 77-88
174. Jacobsen H., Mestan J., Mittnacht S., and Dieffenbach C.W. Beta IFN subtype 1 induction by tumor necrosis factor. Mol Cell Biol 9 (1989) 3037-3042
175. Poupart P., Vandenabeele P., Cayphas S., Van Snick J., Haegeman G., Kruys V., et al. B cell growth modulating and differentiating activity of recombinant human 26-kd protein (BSF-2, HuIFN-beta 2, HPGF). EMBO J 6 (1987) 1219-1224
176. Weissenbach J., Chernajovsky Y., Zeevi M., Shulman L., Soreq H., Nir U., et al. Two IFN mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci USA 77 (1980) 7152-7156
177. Content J., De Wit L., Pierard D., Derynck R., De Clercq E., and Fiers W. Secretory proteins induced in human fibroblasts under conditions used for the production of IFN β. Proc Natl Acad Sci USA 79 (1982) 2768-2772
178. 2-amino acid sequences of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc Natl Acad Sci USA 83 (1986) 9679-9683
179. Billiau A. BSF-2 is not just a differentiation factor. Nature 324 (1986) 415
180. 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin-1 and tumor necrosis factor. J Exp Med 165 (1987) 914-919
181. Haegeman G., Content J., Volckaert G., Derynck R., Tavernier J., and Fiers W. Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts. Eur J Biochem 159 (1986) 625-632
182. Hirano T., Yasukawa K., Harada H., Taga T., Watanabe Y., Matsuda T., et al. Complementary DNA for a novel human interleukin (BSF-2) that induces
183. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 8 (1990) 253-278
184. De Maeyer E., and De Maeyer-Guignard J. Type I IFNs. In: Bona C.A., and Revillard J.-P. (Eds). Cytokines and cytokine receptors. Physiology and pathological disorders (2000), Harwood Academic Publishers 316-333
185. Johnson H.M., Bazer F.W., Szente B.E., and Jarpe M.A. How IFNs fight disease. Scientific Am 270 (1994) 40-47
186. Kimura T., Kadokawa Y., Harada H., Matsumoto M., Sato M., Kashiwazaki Y., et al. Essential and non redundant roles of p48 (ISGF3γ) and IRF-1 in both type I and type II IFN responses, as revealed by gene targeting studies. Genes Cells 1 (1996) 115-124